Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dietger Niederwieser

Showing results (1-10 of 329) with videos related to

Pageof 33
Sort By:
Current Problems in Dermatology|March 2, 2012
History of hematopoietic stem cell transplantation: evolution and perspectivesAlois Gratwohl, Dietger Niederwieser
Seminars in Oncology|August 10, 2002
Bendamustine in the treatment of multiple myeloma: results and future perspectivesWolfram Pönisch, Dietger Niederwieser
European Journal of Haematology|December 24, 2010
Biosimilar agents in oncology/haematology: from approval to practiceDietger Niederwieser, Stephan Schmitz
Health Physics|May 7, 2010
The role of the European haematologist in a large irradiation emergency: the European Blood and Marrow Transplantation Society (EBMT) Nuclear Accident Committee (NAC)Ray Powles, Bhawna Sirohi, Dietger Niederwieser
Cells, Tissues, Organs|January 25, 2008
The case for a metabolic stem cell nicheMichael Cross, Rüdiger Alt, Dietger Niederwieser
Hematology. American Society of Hematology. Education Program|December 10, 2021
Increasing access to allogeneic hematopoietic cell transplant: an international perspectiveVanderson Rocha, Giancarlo Fatobene, Dietger Niederwieser, et al.
Journal of Geriatric Oncology|February 4, 2014
The role of hypomethylating agents in the treatment of elderly patients with AMLHaifa Kathrin Al-Ali, Nadja Jaekel, Dietger Niederwieser
Journal of Clinical Pathology|April 1, 2010
Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapyUdo Siebolts, Thoralf Lange, Dietger Niederwieser, et al.
Blood Cell Therapy|May 23, 2023
The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the worldShinichiro Okamoto, Miguel-Angel Perales, Anna Sureda, et al.
Tissue Engineering. Part A|February 27, 2010
A survey on cellular and engineered tissue therapies in europe in 2008Ivan Martin, Helen Baldomero, Alan Tyndall, et al.
Pageof 33

Showing results (1-10 of 329) with videos related to

Sort By:
Pageof 33
Current Problems in Dermatology|March 2, 2012
History of hematopoietic stem cell transplantation: evolution and perspectivesAlois Gratwohl, Dietger Niederwieser
Seminars in Oncology|August 10, 2002
Bendamustine in the treatment of multiple myeloma: results and future perspectivesWolfram Pönisch, Dietger Niederwieser
European Journal of Haematology|December 24, 2010
Biosimilar agents in oncology/haematology: from approval to practiceDietger Niederwieser, Stephan Schmitz
Health Physics|May 7, 2010
The role of the European haematologist in a large irradiation emergency: the European Blood and Marrow Transplantation Society (EBMT) Nuclear Accident Committee (NAC)Ray Powles, Bhawna Sirohi, Dietger Niederwieser
Cells, Tissues, Organs|January 25, 2008
The case for a metabolic stem cell nicheMichael Cross, Rüdiger Alt, Dietger Niederwieser
Hematology. American Society of Hematology. Education Program|December 10, 2021
Increasing access to allogeneic hematopoietic cell transplant: an international perspectiveVanderson Rocha, Giancarlo Fatobene, Dietger Niederwieser, et al.
Journal of Geriatric Oncology|February 4, 2014
The role of hypomethylating agents in the treatment of elderly patients with AMLHaifa Kathrin Al-Ali, Nadja Jaekel, Dietger Niederwieser
Journal of Clinical Pathology|April 1, 2010
Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapyUdo Siebolts, Thoralf Lange, Dietger Niederwieser, et al.
Blood Cell Therapy|May 23, 2023
The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the worldShinichiro Okamoto, Miguel-Angel Perales, Anna Sureda, et al.
Tissue Engineering. Part A|February 27, 2010
A survey on cellular and engineered tissue therapies in europe in 2008Ivan Martin, Helen Baldomero, Alan Tyndall, et al.
Pageof 33